{"product_id":"sacituzumab-govitecan-plus-pembrolizumab-a-new-first-line-treatment-option-for-advanced-triple-negative-breast-cancer","title":"Sacituzumab Govitecan Plus Pembrolizumab: A New First-Line Treatment Option for Advanced Triple-Negative Breast Cancer","description":"\u003cp\u003eIn this phase 3 clinical trial called ASCENT-04\/KEYNOTE-D19, researchers tested a new combination treatment for people with advanced triple-negative breast cancer (TNBC), the most aggressive form of breast cancer. The study enrolled 443 patients with previously untreated, PD-L1-positive (a protein marker that helps the immune system recognize tumors) advanced TNBC. Patients who received sacituzumab govitecan (Trodelvy) plus pembrolizumab (Keytruda) lived without their cancer growing for a median of 11.2 months, compared with 7.8 months for those who received standard chemotherapy plus pembrolizumab — a 35% reduction in the risk of disease progression or death that was highly statistically significant (P\u0026lt;0.001). This new combination represents a meaningful advance for patients with this difficult-to-treat cancer.\u003c\/p\u003e\n\n\u003ch1\u003eSacituzumab Govitecan Plus Pembrolizumab: A New First-Line Treatment Option for Advanced Triple-Negative Breast Cancer\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eUnderstanding Triple-Negative Breast Cancer\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#why-it-matters\"\u003eWhy This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#study-design\"\u003eHow the Study Was Designed\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#participants\"\u003eWho Participated in the Study\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#pfs-results\"\u003eKey Finding: Longer Time Before Cancer Progression\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#response-results\"\u003eKey Finding: Tumor Shrinkage and Duration of Response\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#safety\"\u003eSafety and Side Effects\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eQuestions to Ask Your Doctor\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIn a phase 3 trial of 443 patients, sacituzumab govitecan plus pembrolizumab delayed cancer progression by a median of 11.2 months vs 7.8 months with chemotherapy plus pembrolizumab.\u003c\/li\u003e\n\u003cli\u003eThe combination reduced the risk of disease progression or death by 35% compared to standard treatment in PD-L1-positive advanced triple-negative breast cancer.\u003c\/li\u003e\n\u003cli\u003eTumor responses lasted nearly twice as long with the new combination: median 16.5 months vs 9.2 months.\u003c\/li\u003e\n\u003cli\u003eFewer patients stopped treatment due to side effects with sacituzumab govitecan plus pembrolizumab (12%) than with chemotherapy plus pembrolizumab (31%).\u003c\/li\u003e\n\u003cli\u003eOverall survival data are not yet mature; longer follow-up is needed to determine if the new combination improves how long patients live.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eUnderstanding Triple-Negative Breast Cancer\u003c\/h2\u003e\n\n\u003cp\u003eBreast cancer is the leading cause of cancer-related death in women worldwide. Among all breast cancer types, triple-negative breast cancer is the most aggressive subtype. The name comes from the fact that these tumors lack three key features: they do not express estrogen receptors (ER), they do not express progesterone receptors (PR), and they have low or no expression of human epidermal growth factor receptor 2 (HER2).\u003c\/p\u003e\n\n\u003cp\u003eBecause these tumors lack those three targets, many standard hormone-based or HER2-directed therapies do not work for them. This makes treatment more challenging.\u003c\/p\u003e\n\n\u003cp\u003eFor people with metastatic triple-negative breast cancer (cancer that has spread beyond the breast), the outlook has historically been poor. The 5-year relative survival rate is approximately 15%, meaning only about 15 out of every 100 patients live at least 5 years after diagnosis.\u003c\/p\u003e\n\n\u003cp\u003eAbout 40% of triple-negative breast cancer cases are PD-L1–positive. PD-L1 (programmed death ligand 1) is a protein found on the surface of some cancer cells. It acts like a \"brake\" on the immune system, preventing immune cells from attacking the tumor. The combined positive score (CPS) measures how much PD-L1 is present by counting PD-L1-staining tumor cells, lymphocytes, and macrophages, dividing by the total number of viable tumor cells, and multiplying by 100. A CPS of 10 or higher is considered PD-L1–positive in this setting.\u003c\/p\u003e\n\n\u003ch2 id=\"why-it-matters\"\u003eWhy This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eThe current preferred first-line treatment for patients with previously untreated, PD-L1–positive metastatic triple-negative breast cancer is pembrolizumab (Keytruda), a type of immunotherapy called a PD-1 immune checkpoint inhibitor, combined with chemotherapy. This recommendation is based on a previous phase 3 trial called KEYNOTE-355.\u003c\/p\u003e\n\n\u003cp\u003eIn that earlier trial, pembrolizumab plus chemotherapy (taxanes or gemcitabine–carboplatin) resulted in significantly longer progression-free survival than chemotherapy alone — a median of 9.7 months versus 5.6 months. Overall survival was also longer: 23.0 months versus 16.1 months among patients whose tumors expressed PD-L1 with a CPS of 10 or higher.\u003c\/p\u003e\n\n\u003cp\u003eDespite this progress, there is still room for improvement. Approximately half of all patients with metastatic triple-negative breast cancer never receive treatment beyond their first line of therapy. This means the first treatment patients receive is especially important — it may be their only opportunity for effective disease control.\u003c\/p\u003e\n\n\u003cp\u003eSacituzumab govitecan (marketed as Trodelvy) is a different type of drug called an antibody–drug conjugate. It is built from a humanized antibody that targets a protein called Trop-2 (trophoblast cell-surface antigen 2), which is found on the surface of many cancer cells. The antibody is attached to a chemotherapy drug called SN-38, a topoisomerase I inhibitor, through a special hydrolyzable linker. This design allows the drug to deliver chemotherapy directly to cancer cells.\u003c\/p\u003e\n\n\u003cp\u003eSacituzumab govitecan is already approved in multiple countries for patients with metastatic triple-negative breast cancer after at least two prior systemic therapies (at least one given for metastatic disease). That approval was based on the phase 3 ASCENT trial, which showed significant improvements in both progression-free and overall survival with sacituzumab govitecan compared with chemotherapy in that later-line setting.\u003c\/p\u003e\n\n\u003cp\u003eThe ASCENT-04\/KEYNOTE-D19 trial asked a new question: Could sacituzumab govitecan be used \u003cem\u003eearlier\u003c\/em\u003e — as part of the first treatment patients receive for advanced disease — when combined with pembrolizumab?\u003c\/p\u003e\n\n\u003ch2 id=\"study-design\"\u003eHow the Study Was Designed\u003c\/h2\u003e\n\n\u003cp\u003eThis was a phase 3, open-label (meaning both patients and doctors knew which treatment was given), randomized international trial conducted at 186 sites in 28 countries. The study enrolled adults with locally advanced unresectable (cancer that cannot be removed with surgery) or metastatic triple-negative breast cancer whose tumors were PD-L1–positive with a CPS of 10 or higher. Patients must not have received any prior therapy for advanced disease.\u003c\/p\u003e\n\n\u003cp\u003eTriple-negative status was confirmed centrally on tumor samples. To qualify, tumors had to have less than 1% of cells positive for estrogen receptor or progesterone receptor, and a HER2 immunohistochemistry (IHC) result of 0, 1+, or 2+ with negative in situ hybridization. PD-L1 expression was measured using the PD-L1 IHC 22C3 pharmDx assay (Dako, Agilent Technologies).\u003c\/p\u003e\n\n\u003cp\u003eEligible patients were randomly assigned in a 1:1 ratio — like a coin flip — to receive one of two treatments:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSacituzumab govitecan plus pembrolizumab:\u003c\/strong\u003e Sacituzumab govitecan was given intravenously at a dose of 10 mg per kilogram of body weight on days 1 and 8 of each 21-day cycle. Pembrolizumab was given intravenously at a fixed dose of 200 mg on day 1 of each 21-day cycle.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eChemotherapy plus pembrolizumab (the control group):\u003c\/strong\u003e Patients received one of three chemotherapy options chosen by their doctor — paclitaxel at 90 mg per square meter of body-surface area, or nanoparticle albumin-bound paclitaxel (nab-paclitaxel) at 100 mg per square meter, both given on days 1, 8, and 15 of 28-day cycles; or gemcitabine at 1000 mg per square meter plus carboplatin (dosed to target an area under the concentration–time curve of 2 mg per milliliter per minute) given on days 1 and 8 of 21-day cycles. Pembrolizumab was given at 200 mg on day 1 of each 21-day cycle.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePatients were divided into groups (stratified) at randomization based on three factors:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDisease status:\u003c\/strong\u003e metastatic disease at initial diagnosis, disease that recurred within 6 to 12 months after completing curative-intent treatment, or disease that recurred more than 12 months after completing curative-intent treatment\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGeographic region:\u003c\/strong\u003e Canada, the United States, or western Europe versus the rest of the world\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePrevious exposure\u003c\/strong\u003e to an anti–PD-1 or anti–PD-L1 agent given as adjuvant or neoadjuvant (before or after surgery) therapy: yes versus no\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eTreatment continued until disease progression was confirmed by blinded independent central review (an independent panel of radiologists who did not know which treatment patients received), the development of unacceptable side effects, withdrawal of consent, or death. Pembrolizumab was given for a maximum of 35 cycles.\u003c\/p\u003e\n\n\u003cp\u003eImportantly, the trial included a \u003cstrong\u003ecrossover phase\u003c\/strong\u003e. Patients who had received chemotherapy plus pembrolizumab could receive sacituzumab govitecan as a single agent after their disease was confirmed to have progressed, if they met eligibility criteria.\u003c\/p\u003e\n\n\u003cp\u003eThe primary end point (the main question the trial was designed to answer) was \u003cstrong\u003eprogression-free survival\u003c\/strong\u003e — the length of time from randomization until the cancer grew or the patient died, whichever came first, as judged by blinded independent central review.\u003c\/p\u003e\n\n\u003cp\u003eKey secondary end points included:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOverall survival\u003c\/strong\u003e (how long patients lived)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eObjective response\u003c\/strong\u003e — whether tumors shrank partially or disappeared completely\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDuration of response\u003c\/strong\u003e — how long tumor shrinkage lasted\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTime to response\u003c\/strong\u003e — how quickly tumors responded\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eSafety\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eTumor assessments were performed with computed tomography (CT) or magnetic resonance imaging (MRI) every 8 weeks during the first 18 months, then every 12 weeks until disease progression was confirmed. Tumor response was measured using standard criteria called RECIST version 1.1 (Response Evaluation Criteria in Solid Tumors).\u003c\/p\u003e\n\n\u003cp\u003eThe trial was designed to enroll approximately 440 patients. For the primary analysis, 227 events of disease progression or death would provide 90% power to detect a hazard ratio of 0.65 at a two-sided significance level of 5%. The trial used a hierarchical testing approach to control the overall error rate.\u003c\/p\u003e\n\n\u003ch2 id=\"participants\"\u003eWho Participated in the Study\u003c\/h2\u003e\n\n\u003cp\u003eA total of \u003cstrong\u003e443 patients\u003c\/strong\u003e were enrolled between October 17, 2022, and August 21, 2024. Of these, 221 were assigned to receive sacituzumab govitecan plus pembrolizumab, and 222 were assigned to receive chemotherapy plus pembrolizumab. The two groups were well balanced in their characteristics.\u003c\/p\u003e\n\n\u003cp\u003eKey baseline characteristics included:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedian age:\u003c\/strong\u003e 54 years (range, 23 to 88) in the sacituzumab govitecan group versus 55 years (range, 27 to 82) in the chemotherapy group\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAge 65 or older:\u003c\/strong\u003e 58 patients (26%) in each group\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFemale sex:\u003c\/strong\u003e 100% of patients in both groups (221 and 222 patients, respectively)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRace:\u003c\/strong\u003e White — 139 (63%) versus 118 (53%); Asian — 43 (19%) versus 63 (28%); American Indian or Alaska Native — 14 (6%) versus 13 (6%); Black — 13 (6%) versus 11 (5%); other or not specified — 12 (5%) versus 17 (8%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGeographic region:\u003c\/strong\u003e Canada, United States, or western Europe — 85 patients (38%) in each group; rest of the world — 136 (62%) versus 137 (62%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eECOG performance status:\u003c\/strong\u003e A score of 0 (fully active) was seen in 156 patients (71%) versus 154 (69%); a score of 1 (restricted in strenuous activity but able to walk and do light work) in 65 (29%) versus 67 (30%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePD-L1–positive status:\u003c\/strong\u003e 100% of patients in both groups, as required by the enrollment criteria\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePatients' disease status at enrollment was also similar:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMetastatic at initial diagnosis:\u003c\/strong\u003e 75 patients (34%) in each group\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRecurrent within 6–12 months\u003c\/strong\u003e after completing curative-intent treatment: 40 patients (18%) in each group\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRecurrent more than 12 months\u003c\/strong\u003e after completing curative-intent treatment: 106 (48%) versus 107 (48%)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eMetastatic sites at baseline included lymph nodes (159 [72%] versus 154 [69%]), lung (111 [50%] versus 95 [43%]), liver (55 [25%] versus 57 [26%]), bone (61 [28%] versus 45 [20%]), brain (8 [4%] versus 6 [3%]), and other sites such as pleura, skin, soft tissue, chest wall, and muscle (81 [37%] versus 71 [32%]).\u003c\/p\u003e\n\n\u003cp\u003eOnly a small number of patients had previously received anti–PD-1 or anti–PD-L1 therapy in the adjuvant or neoadjuvant setting: 9 patients (4%) in the sacituzumab govitecan group and 11 patients (5%) in the chemotherapy group, based on the clinical database.\u003c\/p\u003e\n\n\u003cp\u003eAmong the 220 patients who actually received chemotherapy plus pembrolizumab, 113 (51%) received a taxane (paclitaxel or nab-paclitaxel), and 107 (49%) received gemcitabine plus carboplatin.\u003c\/p\u003e\n\n\u003cp\u003eAt the data cutoff date of March 3, 2025, the median follow-up was \u003cstrong\u003e14.0 months\u003c\/strong\u003e (range, 0.1 to 28.6 months).\u003c\/p\u003e\n\n\u003ch2 id=\"pfs-results\"\u003eKey Finding: Longer Time Before Cancer Progression\u003c\/h2\u003e\n\n\u003cp\u003eThe main result of the trial was clear: patients receiving sacituzumab govitecan plus pembrolizumab experienced significantly longer progression-free survival than those receiving chemotherapy plus pembrolizumab.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedian progression-free survival:\u003c\/strong\u003e 11.2 months (95% confidence interval [CI], 9.3 to 16.7) with sacituzumab govitecan plus pembrolizumab versus 7.8 months (95% CI, 7.3 to 9.3) with chemotherapy plus pembrolizumab\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHazard ratio for disease progression or death:\u003c\/strong\u003e 0.65 (95% CI, 0.51 to 0.84; two-sided P\u0026lt;0.001)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eA hazard ratio of 0.65 means that patients in the sacituzumab govitecan group had a \u003cstrong\u003e35% lower risk\u003c\/strong\u003e of their cancer progressing or dying at any given time compared with the chemotherapy group. The P value of less than 0.001 means there is less than a 0.1% chance this result was due to random chance — a result that is considered highly statistically significant.\u003c\/p\u003e\n\n\u003cp\u003ePut in absolute terms: at 6 months, approximately 72 out of 100 patients (72%, 95% CI 65–77) in the sacituzumab govitecan group were alive without disease progression, compared with 63 out of 100 (63%, 95% CI 56–69) in the chemotherapy group. At 12 months, the difference was larger: approximately 48 out of 100 (48%, 95% CI 41–56) versus 33 out of 100 (33%, 95% CI 26–40). At 18 months, the corresponding figures were about 33 out of 100 versus about 20 out of 100 patients.\u003c\/p\u003e\n\n\u003cp\u003eThe results were consistent when doctors (rather than the blinded central reviewers) assessed progression. Investigator-assessed median progression-free survival was 11.3 months (95% CI, 9.2 to 14.6) with sacituzumab govitecan plus pembrolizumab versus 8.3 months (95% CI, 7.3 to 9.3) with chemotherapy plus pembrolizumab (hazard ratio, 0.67; 95% CI, 0.52 to 0.87).\u003c\/p\u003e\n\n\u003cp\u003eThe progression-free survival benefit was consistent across all predefined patient subgroups, including those defined according to age, disease status, and geographic region.\u003c\/p\u003e\n\n\u003cp\u003eA total of 109 events of disease progression or death occurred in the sacituzumab govitecan group, compared with 140 in the chemotherapy group.\u003c\/p\u003e\n\n\u003cp\u003eAt the time of the primary analysis, \u003cstrong\u003eoverall survival data were not yet mature\u003c\/strong\u003e. Only 26% of the total number of patients had died, and the median overall survival had not been reached in either group. This means the trial is still ongoing, and longer follow-up will be needed to determine whether the new combination extends life overall.\u003c\/p\u003e\n\n\u003cp\u003eOf note, 119 patients who stopped chemotherapy plus pembrolizumab went on to receive subsequent treatment. Of these, 96 patients (81%) received sacituzumab govitecan as their next anticancer therapy through the crossover phase. This crossover may affect the final overall survival comparison, because many patients in the chemotherapy group eventually received the investigational drug.\u003c\/p\u003e\n\n\u003cp\u003eMore patients in the sacituzumab govitecan group were still receiving treatment at the data cutoff: 95 patients (43%) versus 52 patients (23%). The most common reasons for stopping the sacituzumab govitecan or chemotherapy were disease progression (in 37% versus 55% of patients) and adverse events (in 8% versus 18%). For pembrolizumab specifically, the most common reasons for discontinuation were disease progression (37% versus 58%) and adverse events (10% versus 14%).\u003c\/p\u003e\n\n\u003ch2 id=\"response-results\"\u003eKey Finding: Tumor Shrinkage and Duration of Response\u003c\/h2\u003e\n\n\u003cp\u003eThe objective response rate — the percentage of patients whose tumors shrank partially or disappeared completely — was higher with the sacituzumab govitecan combination:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eObjective response rate:\u003c\/strong\u003e 60% (95% CI, 53 to 66) with sacituzumab govitecan plus pembrolizumab versus 53% (95% CI, 46 to 60) with chemotherapy plus pembrolizumab\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn absolute terms, this means about 60 out of 100 patients in the sacituzumab govitecan group had their tumors shrink, versus about 53 out of 100 in the chemotherapy group.\u003c\/p\u003e\n\n\u003cp\u003ePerhaps even more importantly, among patients whose tumors responded, the response lasted substantially longer:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedian duration of response:\u003c\/strong\u003e 16.5 months (95% CI, 12.7 to 19.5) with sacituzumab govitecan plus pembrolizumab versus 9.2 months (95% CI, 7.6 to 11.3) with chemotherapy plus pembrolizumab\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis means that when the cancer did respond to the new combination, the response lasted a median of more than 16 months — nearly twice as long as responses in the chemotherapy group.\u003c\/p\u003e\n\n\u003ch2 id=\"safety\"\u003eSafety and Side Effects\u003c\/h2\u003e\n\n\u003cp\u003eBoth treatment combinations caused side effects, and the overall rates of serious side effects were similar between the two groups. The safety profile observed in this trial was consistent with what is already known about these drugs from earlier studies.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGrade 3 or higher adverse events\u003c\/strong\u003e (severe side effects requiring medical intervention): occurred in \u003cstrong\u003e71%\u003c\/strong\u003e of patients receiving sacituzumab govitecan plus pembrolizumab versus \u003cstrong\u003e70%\u003c\/strong\u003e of those receiving chemotherapy plus pembrolizumab\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTreatment discontinuation due to adverse events:\u003c\/strong\u003e 12% in the sacituzumab govitecan group versus 31% in the chemotherapy group\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAdverse events leading to death:\u003c\/strong\u003e 3% in each group\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOne notable finding is that patients receiving chemotherapy plus pembrolizumab were more than twice as likely to stop treatment because of side effects (31% versus 12%). This suggests the sacituzumab govitecan combination may be better tolerated overall, despite similar rates of severe side effects.\u003c\/p\u003e\n\n\u003cp\u003eAdverse events were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 27.1 and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The relationship of each event to the trial drugs was assessed by the investigator.\u003c\/p\u003e\n\n\u003cp\u003ePatients should discuss the specific side effect profiles — including common side effects such as diarrhea, low white blood cell counts (neutropenia), nausea, and fatigue — with their oncology team. The trial publication focuses on overall safety rates; detailed side-effect lists are included in the Supplementary Appendix.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThis trial provides strong evidence that sacituzumab govitecan plus pembrolizumab is a more effective first-line treatment than the current standard of chemotherapy plus pembrolizumab for patients with PD-L1–positive advanced triple-negative breast cancer. The benefit was seen in an international, diverse patient population treated at 186 sites across 28 countries.\u003c\/p\u003e\n\n\u003cp\u003eThe key takeaways for patients are:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBetter progression-free survival:\u003c\/strong\u003e The new combination delayed cancer growth by an average of about 3.4 additional months compared with standard treatment (11.2 months versus 7.8 months). Longer follow-up will determine whether this translates into longer overall survival.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMore durable responses:\u003c\/strong\u003e When tumors responded, they stayed under control nearly twice as long with sacituzumab govitecan (16.5 months versus 9.2 months). This durability can matter more than the initial response rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFewer treatment discontinuations:\u003c\/strong\u003e Only 12% of patients stopped the sacituzumab govitecan combination due to side effects, versus 31% in the chemotherapy group — a potentially important quality-of-life consideration.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eA meaningful treatment option:\u003c\/strong\u003e Sacituzumab govitecan is already approved and available for later-line treatment of metastatic TNBC. Its use earlier in the disease course, in combination with pembrolizumab, may become a new standard of care.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFor patients newly diagnosed with PD-L1–positive advanced triple-negative breast cancer, this study supports discussing sacituzumab govitecan plus pembrolizumab with their oncologist as a potential first-line treatment option.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations\u003c\/h2\u003e\n\n\u003cp\u003eEvery clinical trial has limitations, and it is important for patients to understand what this study could and could not show.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOverall survival data are immature.\u003c\/strong\u003e Only 26% of patients had died at the time of data cutoff, and median overall survival was not reached in either group. It remains unknown whether the new combination improves how long patients live, not just how long they live without cancer progression.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCrossover may dilute survival differences.\u003c\/strong\u003e Because 81% of patients in the chemotherapy group who received subsequent therapy went on to receive sacituzumab govitecan, any eventual difference in overall survival between the two groups may be smaller than the true benefit of the drug.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe trial was open-label.\u003c\/strong\u003e Both patients and doctors knew which treatment was being given. Although the primary end point was assessed by blinded independent central review (which reduces bias), open-label designs can still influence patient-reported outcomes and management decisions.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe population was limited to PD-L1–positive patients.\u003c\/strong\u003e These results apply only to patients whose tumors have a CPS of 10 or higher. They do not apply to the roughly 60% of triple-negative breast cancer patients whose tumors are PD-L1–negative.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOnly female patients were enrolled.\u003c\/strong\u003e Although triple-negative breast cancer occurs overwhelmingly in women, the results may not fully apply to the rare male patients with this disease.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNo health-related quality-of-life data were reported in this publication.\u003c\/strong\u003e Patient-reported outcomes were collected but not included in this report, so we cannot yet assess whether the longer progression-free survival translates into better quality of life.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe 95% confidence intervals for secondary end points\u003c\/strong\u003e (such as response rate and duration of response) were not adjusted for multiple comparisons, meaning those results should be interpreted with some caution.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eQuestions to Ask Your Doctor\u003c\/h2\u003e\n\n\u003cp\u003eIf you or a loved one has been diagnosed with PD-L1–positive advanced triple-negative breast cancer, this research may be relevant to your treatment discussions. Consider asking your oncology team the following questions:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIs my tumor PD-L1 positive?\u003c\/strong\u003e — Ask about your combined positive score (CPS) and whether it is 10 or higher, since this trial only included patients with CPS of 10 or above.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWould sacituzumab govitecan plus pembrolizumab be an appropriate first-line treatment for me?\u003c\/strong\u003e — This combination is not yet universally approved, so availability and insurance coverage may vary by region.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWhat are the expected side effects?\u003c\/strong\u003e — Ask specifically about diarrhea, low blood counts, nausea, fatigue, and immune-related side effects from pembrolizumab, and how these would be managed.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWhat chemotherapy options would I otherwise receive?\u003c\/strong\u003e — The trial compared the new combination with taxane-based or gemcitabine–carboplatin regimens, so ask how those compare in your situation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIs there a clinical trial I might qualify for?\u003c\/strong\u003e — If the combination is not yet approved where you live, a clinical trial may be an avenue to access it.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWhat are my options if the first treatment stops working?\u003c\/strong\u003e — In this trial, patients could receive sacituzumab govitecan after progression, so ask about sequencing of treatments.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe results of this trial are encouraging, but treatment decisions are always personal. Your medical team can help you weigh the potential benefits against the risks based on your specific situation.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is triple-negative breast cancer and why is it hard to treat?\u003c\/h3\u003e\n\u003cp\u003eTriple-negative breast cancer (TNBC) is an aggressive subtype that lacks estrogen, progesterone, and HER2 receptors, so hormone or HER2-targeted therapies don't work. About 40% of TNBC cases are PD-L1 positive, meaning they have a protein that can be targeted by immunotherapy. This makes treatment challenging, but new combinations are being studied.\u003c\/p\u003e\n\u003ch3\u003eWho was eligible for this clinical trial?\u003c\/h3\u003e\n\u003cp\u003eThe trial enrolled adults with advanced triple-negative breast cancer that was PD-L1 positive (CPS of 10 or higher), had not received prior therapy for advanced disease, and was either metastatic or locally advanced unresectable. Patients had to have confirmed triple-negative status and no prior treatment for advanced disease. Both women and men were eligible, but only women enrolled.\u003c\/p\u003e\n\u003ch3\u003eWhat were the main results of the trial?\u003c\/h3\u003e\n\u003cp\u003eIn the trial of 443 patients, those receiving sacituzumab govitecan plus pembrolizumab lived without cancer progression for a median of 11.2 months, compared to 7.8 months for those on chemotherapy plus pembrolizumab. This was a 35% reduction in risk of progression or death, and the difference was highly statistically significant.\u003c\/p\u003e\n\u003ch3\u003eWhat side effects were seen with the new combination?\u003c\/h3\u003e\n\u003cp\u003eSevere side effects (grade 3 or higher) occurred in 71% of patients on sacituzumab govitecan plus pembrolizumab versus 70% on chemotherapy plus pembrolizumab. However, fewer patients stopped treatment due to side effects with the new combination (12% versus 31%). Common side effects included diarrhea, low white blood cell counts, nausea, and fatigue.\u003c\/p\u003e\n\u003ch3\u003eIs this new treatment available now?\u003c\/h3\u003e\n\u003cp\u003eSacituzumab govitecan is already approved for later-line treatment of metastatic triple-negative breast cancer, but its use in combination with pembrolizumab as first-line therapy is not yet universally approved. Availability and insurance coverage may vary by region, so patients should discuss with their oncologist and consider clinical trials if not approved.\u003c\/p\u003e\n\u003ch3\u003eWhat are the limitations of this study?\u003c\/h3\u003e\n\u003cp\u003eOverall survival data are not yet mature, so it's unknown if the new combination improves how long patients live. The trial was open-label, and many patients in the chemotherapy group later received sacituzumab govitecan, which may dilute survival differences. Results apply only to PD-L1-positive patients with CPS of 10 or higher.\u003c\/p\u003e\n\u003ch3\u003eI have PD-L1-positive advanced triple-negative breast cancer and my doctor recommends sacituzumab govitecan plus pembrolizumab as first-line treatment. Should I get a second opinion before starting?\u003c\/h3\u003e\n\u003cp\u003eA second opinion can help confirm that sacituzumab govitecan plus pembrolizumab is the right first-line choice for your PD-L1-positive advanced triple-negative breast cancer. This trial showed it delays cancer growth longer than chemotherapy plus pembrolizumab (median 11.2 vs 7.8 months) and responses last nearly twice as long. However, overall survival data are not yet mature, and the combination may not be universally approved or covered. A second opinion can also clarify side effects and alternative options. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article:\u003c\/strong\u003e \"Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer\" by S.M. Tolaney, E. de Azambuja, K. Kalinsky, S. Loi, S.-B. Kim, C. Yam, B. Rapoport, S.-A. Im, B. Pistilli, W. Mchayleh, D.W. Cescon, J. Watanabe, M.A.L. Bañuelas, R. Freitas-Junior, J. Salvador Bofill, M. Afshari, D. Gary, L. Wang, C. Lai, and P. Schmid, for the ASCENT-04\/KEYNOTE-D19 Clinical Trial Investigators.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e \u003cem\u003eThe New England Journal of Medicine\u003c\/em\u003e, 2026; volume 394, pages 354–366. DOI: 10.1056\/NEJMoa2508959.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eTrial registration:\u003c\/strong\u003e ClinicalTrials.gov number NCT05382286. Funded by Gilead Sciences, conducted in collaboration with Merck Sharp and Dohme (a subsidiary of Merck).\u003c\/p\u003e\n\n\u003cp\u003eThis patient-friendly article is based on peer-reviewed research published in \u003cem\u003eThe New England Journal of Medicine\u003c\/em\u003e. It is intended for educational purposes and does not constitute medical advice. Always consult your healthcare team about diagnosis and treatment options.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47494457458844,"sku":null,"price":0.0,"currency_code":"KRW","in_stock":true}],"url":"https:\/\/diagnosticdetectives.kr\/products\/sacituzumab-govitecan-plus-pembrolizumab-a-new-first-line-treatment-option-for-advanced-triple-negative-breast-cancer","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}